<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ac Immune Ltd — News on 6ix</title>
<link>https://6ix.com/company/ac-immune-ltd</link>
<description>Latest news and press releases for Ac Immune Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 11:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ac-immune-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835420c78dffbe2df0e11e6.webp</url>
<title>Ac Immune Ltd</title>
<link>https://6ix.com/company/ac-immune-ltd</link>
</image>
<item>
<title>AC Immune First Quarter 2026 Financial and Corporate Updates</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-first-quarter-2026-financial-and-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-first-quarter-2026-financial-and-corporate-updates</guid>
<pubDate>Thu, 30 Apr 2026 11:05:00 GMT</pubDate>
<description>AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 2026Initiated final cohort, AD4, in ABATE Phase 1b/2 trial of ACI-24 to treat Alzheimer's Disease triggers milestone payment, as announced separately today Amended Morphomer® Tau collaboration with Lilly reflects growing excitement for targeting intracellular Tau and significant pro</description>
</item>
<item>
<title>AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-initiates-final-cohort-in-ongoing-phase-1b2-abate-trial-of-anti-abeta-active-immunotherapy-to-treat-alzheimers-disease</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-initiates-final-cohort-in-ongoing-phase-1b2-abate-trial-of-anti-abeta-active-immunotherapy-to-treat-alzheimers-disease</guid>
<pubDate>Thu, 30 Apr 2026 11:00:00 GMT</pubDate>
<description>AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million milestone paymentAllows evaluation of potential for precision prevention of neurodegenerative diseasesData from ABATE Cohorts AD1, AD2 and AD3 after 12 months treatment expected Q2 2026 Lausanne, Switzerland, April 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical c</description>
</item>
<item>
<title>AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-announces-amendment-to-morphomer-r-tau-license-and-collaboration-agreement-with-lilly</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-announces-amendment-to-morphomer-r-tau-license-and-collaboration-agreement-with-lilly</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for</description>
</item>
<item>
<title>AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-presents-first-in-vivo-images-of-brain-tdp-43-pathology-from-phase-1-trial-of-pet-tracer-aci-19626-at-adpdtm-2026</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-presents-first-in-vivo-images-of-brain-tdp-43-pathology-from-phase-1-trial-of-pet-tracer-aci-19626-at-adpdtm-2026</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026 Initial data indicates</description>
</item>
<item>
<title>AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-reports-full-year-2025-financial-results-and-provides-a-corporate-update-78</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-reports-full-year-2025-financial-results-and-provides-a-corporate-update-78</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy</description>
</item>
<item>
<title>AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-announces-upcoming-industry-symposium-on-parkinsons-disease-and-presentation-at-adpdtm-2026-6</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-announces-upcoming-industry-symposium-on-parkinsons-disease-and-presentation-at-adpdtm-2026-6</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 AC Immune to host symposium highlighting Precision</description>
</item>
<item>
<title>AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-initiates-phase-1-clinical-trial-of-nlrp3-inhibitor</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-initiates-phase-1-clinical-trial-of-nlrp3-inhibitor</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitorNLRP3</description>
</item>
<item>
<title>AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-positive-interim-phase-120000074</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-positive-interim-phase-120000074</guid>
<pubDate>Thu, 11 Dec 2025 12:00:00 GMT</pubDate>
<description>AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease Results show, for the first time, that targeting underlying a-syn pathology with an active immunotherapy could slow the rate of progression of Parkinson’s diseaseClear safety profile with no clinically relevant safety issues reportedTargets met for immunogenicity (100% responder rate), pharmacodynamic effect, target engagement and clinical assessmentsUnderlines potential and im</description>
</item>
<item>
<title>AC Immune to Present at the Jefferies 2025 London Healthcare Conference</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-present-jefferies-2025-120000072</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-present-jefferies-2025-120000072</guid>
<pubDate>Tue, 11 Nov 2025 12:00:00 GMT</pubDate>
<description>AC Immune to Present at the Jefferies 2025 London Healthcare Conference Lausanne, Switzerland, November 11, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025. The fireside chat will take place on Nove</description>
</item>
<item>
<title>AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-reports-third-quarter-120000663</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-reports-third-quarter-120000663</guid>
<pubDate>Tue, 04 Nov 2025 12:00:00 GMT</pubDate>
<description>AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau and a-syn Cash resources of CHF 108.5 million as of September 30, 2025, provide funding to the end of Q3 2027 excluding any income from potential milestonesPeer-reviewed papers covering groundbreaking results including clinical data on ACI-35.030 (JNJ-64042056)</description>
</item>
<item>
<title>AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-appoints-renowned-neurologist-110000463</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-appoints-renowned-neurologist-110000463</guid>
<pubDate>Tue, 28 Oct 2025 11:00:00 GMT</pubDate>
<description>AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia across multiple novel modalitiesIncludes immunotherapies and small molecule drugs targeting intracellular proteinopathiesLeadership in groundbreaking early-stage clinical trials reinforces Company’s competencies Lausanne, Switzerland, October 28, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage bio</description>
</item>
<item>
<title>First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine</title>
<link>https://6ix.com/company/ac-immune-ltd/news/first-characterization-tdp-43-pet-125000256</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/first-characterization-tdp-43-pet-125000256</guid>
<pubDate>Fri, 24 Oct 2025 12:50:00 GMT</pubDate>
<description>First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine Aggregated TDP-43 is a pathological hallmark of neurodegenerative diseases including ALS, FTD and LATE, and a co-pathology in Alzheimer’s and Parkinson’s diseasesPET imaging of aggregated TDP-43 could facilitate precision medicine in these diseases, whose shared clinical features complicate differential diagnosis, potentially delaying therapyBased on s</description>
</item>
<item>
<title>Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine</title>
<link>https://6ix.com/company/ac-immune-ltd/news/peer-reviewed-results-phase-1b-110000292</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/peer-reviewed-results-phase-1b-110000292</guid>
<pubDate>Thu, 25 Sep 2025 11:00:00 GMT</pubDate>
<description>Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054 demonstrated that two different active immunotherapy formulations against the same target can induce a differential antibody response in individuals with early Alzheimer’s diseaseACI-35.030, developed using AC Immune’s SupraAntigen® technology, generated rapid, potent polyclonal response against pat</description>
</item>
<item>
<title>AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-sharpens-pipeline-focus-074500252</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-sharpens-pipeline-focus-074500252</guid>
<pubDate>Thu, 04 Sep 2025 07:45:00 GMT</pubDate>
<description>AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce reduction of around 30%Increased emphasis on late-stage clinical development of active immunotherapy portfolio for Alzheimer’s and Parkinson’s diseases and progressing high value candidates enabling intracellular targetingNear term clinical milestones remain unchangedCash resources of CHF 127.1</description>
</item>
<item>
<title>AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-reports-second-quarter-110000492</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-reports-second-quarter-110000492</guid>
<pubDate>Tue, 05 Aug 2025 11:00:00 GMT</pubDate>
<description>AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical developmentACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson’s disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing Phase 2 VacSYn reported in April, with further data to come in H2 2025Third Alzheimer’s disease cohort (AD3) in the</description>
</item>
<item>
<title>AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-reports-first-quarter-110000410</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-reports-first-quarter-110000410</guid>
<pubDate>Wed, 30 Apr 2025 11:00:00 GMT</pubDate>
<description>AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkinson’s disease (PD)Additional ACI-7104.056 Phase 2 interim results (pharmacodynamics and biomarkers) expected in Q2 2025Presentations</description>
</item>
<item>
<title>AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-reports-further-positive-100000259</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-reports-further-positive-100000259</guid>
<pubDate>Wed, 02 Apr 2025 10:00:00 GMT</pubDate>
<description>AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold higher than placebo after 4 immunizationsRepeated immunizations amplify the anti-a-syn antibody response, supporting boostability and the potential to further increase antibody titersACI-7104.056 is well tolerated with no safety issues reported to</description>
</item>
<item>
<title>AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-announces-upcoming-presentations-110000252</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-announces-upcoming-presentations-110000252</guid>
<pubDate>Tue, 25 Mar 2025 11:00:00 GMT</pubDate>
<description>AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company’s industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseasesMultiple presentations at the International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2025) showcasing the diversity of the company’s precision medicine pipeline Lausanne, Switzerland, March 25, 2025 – AC Immune SA (</description>
</item>
<item>
<title>AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-reports-full-2024-110000174</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-reports-full-2024-110000174</guid>
<pubDate>Thu, 13 Mar 2025 11:00:00 GMT</pubDate>
<description>AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon commercializationACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and tolerability data in Down syndrome (DS) cohort; further interim results in Alzheimer’s disease (AD) and DS expected in 2025Enrollment progr</description>
</item>
<item>
<title>AC Immune to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/ac-immune-ltd/news/ac-immune-participate-upcoming-investor-120000048</link>
<guid isPermaLink="true">https://6ix.com/company/ac-immune-ltd/news/ac-immune-participate-upcoming-investor-120000048</guid>
<pubDate>Tue, 04 Mar 2025 12:00:00 GMT</pubDate>
<description>AC Immune to Participate in Upcoming Investor Conferences Lausanne, Switzerland, March 4, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the company's management will participate in the following investor conferences in March: Leerink Partners 2025 Global Healthcare Conference,Management will participate in investor meetings on March 10, 2025Barclays 27th Annual Global Healthcare Co</description>
</item>
</channel>
</rss>